Demystifying Definitive Healthcare: Insights From 9 Analyst Reviews
Portfolio Pulse from Benzinga Insights
In the last three months, 9 analysts have reviewed Definitive Healthcare (NASDAQ:DH), with ratings ranging from bullish to bearish. The average 12-month price target has decreased by 23.52% to $7.22. Analysts have recently lowered their ratings and price targets, reflecting a more cautious outlook.
July 31, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Definitive Healthcare (NASDAQ:DH) has seen a mixed range of analyst ratings over the past three months, with a notable decrease in the average 12-month price target by 23.52% to $7.22. Analysts have recently lowered their ratings and price targets, indicating a more cautious outlook on the stock.
The significant reduction in the average price target and the lowering of ratings by multiple analysts suggest a bearish short-term outlook for DH. This indicates that analysts are less optimistic about the company's near-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100